Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07397611 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

StatusRecruiting
PhasePhase 2
Started2026-03-09
View on ClinicalTrials.gov ↗

Amendment history

2026-03-18
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2026-07→confirmed 2026-03-09
Study sitesdetails revised at 3 of 3 sites
2026-02-02
Original filing
The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC). The names of the study drugs involved in this study are: * Casdatifan (a type of HIF-2α inhibitor) * Zimberelimab (a type of monoclonal antibody)
Trial Details
NCT Number NCT07397611
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Arcus Biosciences, Inc.
Conditions Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma
Enrollment 32 participants
Start Date 2026-03-09
Primary Completion 2028-01-31 (estimated)
Study Completion 2029-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-20